Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzyl Carbamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.59 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | AGXT | P21549 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Carbamate SCHEMBL6944562 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL30227819 | 0.98 | ALDH1A1 (0.63) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL1697 | 0.98 | ALDH1A1 (0.63) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL10700633 | 0.98 | ALDH1A1 (0.63) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL30227887 | 0.98 | ALDH1A1 (0.63) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL1289962 | 0.96 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL28611022 | 0.96 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL1324825 | 0.96 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL30853229 | 0.96 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Carbamate SCHEMBL28347888 | 0.96 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371866-A | Water-based concrete composite anticorrosive paint and preparation method thereof | 长安大学 | 2025-01-28 | — | — | CN | claimed |
| CN-119768398-A | Heterocyclic compounds which inhibit and/or induce KRAS protein degradation | 安斯泰来制药有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113164481-B | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2024-08-30 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117586256-A | Substituted heterocyclic compounds | 首药控股(北京)股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116406259-A | Dosage form compositions comprising inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116209652-A | Synthesis of pyrrole acid derivatives | 英菲克斯治疗有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-101600691-A | Acyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| WO-2008157726-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101090909-A | Antibacterial amide macrocycles IV | AICURIS GMBH & CO KG (DE) | 2007-12-19 | — | — | CN | disclosed |
| CN-1264843-C | Pyrazolopyrimidinone derivatives having PDE7 inhibitory action | DAIICHI SUNTORY PHARMACEUTICAL (JP) | 2006-07-19 | — | — | CN | disclosed |
| CN-1533392-A | Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity | ��һ��������ҩ��ʽ���� | 2004-09-29 | — | — | CN | disclosed |
| EP-1311292-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140864-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |